$AIP

Alpern Paul L sold $296K of AIP

Alpern Paul L (VP and General Counsel) sold 6,500 shares of Arteris, Inc. (AIP) at an average of $45.46 ($44.02–$47.11, $0.30M total) across 4 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Alpern Paul L
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Neutral
high confidence
Mentioned
$AIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The only new fact is the officer’s planned open-market sale details (shares, price range, total value) and post-transaction holdings; no business developments are mentioned.

02

Market read

Traders may note insider selling, but the 10b5-1 pre-arranged nature makes it low-signal for near-term valuation.

03

What to watch

The filing does not disclose any new company-specific information; traders should avoid extrapolating from a single planned sale without corroborating fundamentals or guidance changes.

Relevance 3/10Novelty 2/10Timing: Filed on 2026-07-02 for a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Arteris, Inc. (AIP).

Company-level read

Ticker impact

$AIPNeutralHigh confidence
Context

Arteris GC Alpern Paul L sold about $296K of AIP shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and should fade as it is pre-arranged.

Evidence & confidence

Form 4 shows a planned 10b5-1 open-market sale by an officer, with no accompanying operational, financial, or regulatory change described.

Market effects

No clear sector read-through; insider sales under 10b5-1 are common and typically not sector-moving.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market reaction should be muted.

Key entities

  • Arteris, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Alpern Paul L

    VP and General Counsel who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to